Valuation: NRx Pharmaceuticals, Inc.

Market Cap 168M 147M 136M 127M 238M 15.85B 244M 1.63B 630M 7.82B 630M 616M 27.15B P/E 2026 *
-10.7x
P/E 2027 * 11.3x
Enterprise Value 168M 147M 136M 127M 238M 15.85B 244M 1.63B 630M 7.82B 630M 616M 27.15B EV / Sales 2026 *
16.4x
EV / Sales 2027 * 1.01x
Free-Float
92.42%
Yield 2026 *
-
Yield 2027 * -
1 day+7.24%
1 week+2.56%
Current month-9.50%
1 month-9.50%
3 months+82.65%
6 months+53.85%
Current year+47.60%
1 week 3.1
Extreme 3.1
4.04
1 month 3.1
Extreme 3.1
5.06
Current year 1.62
Extreme 1.62
5.06
1 year 1.62
Extreme 1.62
5.06
3 years 1.1
Extreme 1.1
7.33
5 years 1.1
Extreme 1.1
262.4
10 years 1.1
Extreme 1.1
769.9
Manager TitleAgeSince
Chief Executive Officer 69 2024-10-06
Director of Finance/CFO 55 2024-11-17
Chief Tech/Sci/R&D Officer - 2026-03-01
Director TitleAgeSince
Chairman 69 2017-09-17
Director/Board Member 77 2021-05-23
Director/Board Member 66 2021-05-23
Date Insider Type Main position Quantity % Market Cap.
Jan. 26Other

Chief Operating Officer

100,000 0.4207%
Jan. 26Free

Chief Operating Officer

100,000 0.4207%
25-08-17
The B Group, Inc.
OtherCompany 3,000,000 12.6210%
Change 5-day change 1-year change 3-year change Capi.($)
+7.24%+2.56%+16.96%-18.37% 168M
+0.94%+7.83%-4.77%+3.17% 46.62B
+5.79%+16.17%+421.86%+634.63% 40.95B
+1.12%+15.18%+22.74%-12.71% 32.26B
+3.61%+6.69%+20.23%+62.38% 32.24B
+8.02%+6.35%+17.67%+34.73% 25.53B
+1.13%+15.66% - - 16.38B
+1.45%+17.35%+72.11%+127.60% 15.27B
-1.13%+7.40%+12.03%+20.67% 13.61B
-0.60%+6.32%+102.74%+96.28% 13.34B
Average +2.76%+10.68%+75.73%+105.38% 23.64B
Weighted average by Cap. +2.78%+11.58%+97.86%+146.08%

Financials

2026 *2027 *
Net sales 10.19M 8.92M 8.24M 7.69M 14.48M 964M 14.81M 99.14M 38.27M 475M 38.27M 37.43M 1.65B 166M 145M 134M 125M 235M 15.66B 241M 1.61B 622M 7.72B 622M 608M 26.82B
Net income -14.73M -12.9M -11.91M -11.12M -20.93M -1.39B -21.41M -143M -55.31M -687M -55.31M -54.1M -2.39B 15.17M 13.28M 12.26M 11.45M 21.55M 1.43B 22.04M 148M 56.96M 708M 56.96M 55.71M 2.46B
Net Debt - -
Logo NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
Employees
29
Date Price Change Volume
26-06-29 $4.000 +7.24% 993,698
26-06-26 $3.730 +4.78% 943,313
26-06-25 $3.560 0.00% 1,237,319
26-06-24 $3.560 -5.32% 2,558,407
26-06-23 $3.760 -3.59% 800,233
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.000USD
Average target price
42.00USD
Spread / Average Target
+950.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NRXP Stock